New drug combo aims to boost blood cell recovery in rare anemia
NCT ID NCT07345000
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether adding romiplostim (a platelet-boosting drug) to standard immunosuppressive therapy helps people with severe aplastic anemia achieve normal blood cell counts. About 210 participants will receive either romiplostim or a placebo alongside standard treatment. The main goal is to see if more patients reach complete blood count recovery at 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- romiplostim (a drug that stimulates platelet production)
- What this could lead to
- If successful, this combination could help more patients achieve normal blood cell counts, reducing dependence on transfusions and infections.
- What could go wrong
- This is an early-stage Phase 3 trial with 210 participants. Results may not apply to all patients, and romiplostim may cause side effects like bone marrow changes or blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT-NAÏVE SEVERE APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.